Dr. Gay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
University of North Carolina at Chapel Hill
101 Manning Drive
Chapel Hill, NC 27514Phone+1 984-974-7198Fax+1 919-966-8928
Summary
- Dr. Cynthia Gay is an infectious disease specialist in Chapel Hill, NC and is affiliated with University of North Carolina Hospitals. She received her medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 18 years. She is experienced in hiv/aids and infectious disease. She has more than 100 publications.
Education & Training
- University of North Carolina HospitalsFellowship, Infectious Disease, 2003 - 2006
- Vanderbilt University Medical CenterResidency, Internal Medicine, 1999 - 2002
- University of North Carolina at Chapel Hill School of MedicineClass of 1999
- University of North Carolina School of Public HealthM.P.H., Maternal and Child Health, 1998
- University of Maryland, College ParkNo degree, Post Graduate Pre Medical Course Work, 1992 - 1993
- Duke UniversityB.A., Interdisciplinary Studies, 1990
Certifications & Licensure
- NC State Medical License 2003 - 2025
- TN State Medical License 2001 - 2004
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Geriatric Medicine
Awards, Honors, & Recognition
- Poster Winner � People�s Favorite, Quality Expo, �OraQuick Testing Utilization in a High Risk Patient Population� UNC School of Medicine, 2013
- Merit Distinction, Scientific Programme Committee, 6th International Conference on HIV Pathogenesis, Treatment and Prevention AIDS Society, 2011
- Clinical Infectious Diseases Award for Outstanding Review 2010
- Join now to see all
Clinical Trials
- HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine Start of enrollment: 2009 Mar 01
- Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) Start of enrollment: 2005 Jan 01
- Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E Janes
Nature Communications. 2024-09-11 - Provider Perspectives on Rapid Treatment Initiation Among People Newly Diagnosed With HIV: A New Message of "Urgency"?Breana J Uhrig Castonguay, Noah Mancuso, Sarah Hatcher, Sable Watson, Eunice Okumu
Journal of the International Association of Providers of AIDS Care. 2024-09-05 - Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.Holly Janes, Leigh H Fisher, Jia Jin Kee, Lalitha Parameswaran, Paul A Goepfert
The Journal of Infectious Diseases. 2024-09-03
Journal Articles
- Results of a Social Network Testing Intervention for HIV in Infectious Disease ClinicsAimee Wilkin, Cynthia L Gay, AIDS and Behavior
- Results of a Social Network Testing Intervention for HIV in Infectious Disease ClinicsLeViere A, Donovan J, Wilkin A, Keller J, Parnell H, Sampson L, Gay CL, Quinlivan EB, AIDS Behav, 1/5/2018
- Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and womenWeber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD, Dellon ES, De Paris K, Nelson JA, Gay CL, Kashuba AD, J Clin Invest, 1/1/2018
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Near full-length sequence analysis reveals no evidence of HIV-1 replication during therapyLee SK, Rogers A, Xu Y, Warren J, Goonetilleke N, Zhou S, Pond SK, Bednar M, Hauser B, Gay C, Kuruc J, Archin N, Eron J, Margolis D, Swanstrom R, 22nd International AIDS Conference, Amsterdam, Netherlands, 1/23/2018
- Altered TDF/FTC pharmacology in a transgender female cohort: Implications for PrePCottrell, ML, Prince HM, Maffuid K, Poliseno A, White N, Sykes C, Nelson JA, Peery A, Dellon E, Hightow-Weidman L, Adams JL, Gay C, Kashuba A, 22nd International AIDS Conference, Amsterdam, Netherlands, 1/23/2018
- Comparing time to viral suppression among acute and non-acute HIV in North CarolinaAdams DA, Cope A, Wheeler B, Mobley V, Barnhart J, Kuruc JD, Gay CL, Filiatreau LM, Ashby R, Samoff E, Conference on Retroviruses and Opportunistic Infections, Boston, MA, 1/4/2018
- Join now to see all
Lectures
- Discuss unknown clinical cases using my clinical experience and knowledge of the medical literatureUniversity of North Carolina, Chapel Hill, NC - 1/1/2018
- Treatment and Prophylaxis of AIDS Opportunistic InfectionsInfectious Diseases Boot Camp for incoming ID fellows - 1/1/2018
- Antibodies & HIV Prevention: Thinking Outside the Box and On TargetChapel Hill, NC - 1/21/2016
- Join now to see all
Other
- Prevention of sexually transmitted infectionsGay CL, Cohen MS
http://www.uptodate.com/contents/prevention-of-sexually-transmitted-infections
UpToDate, Wolters Kluwer Health - 2012-11-15 - HIV � A Global PerspectiveGay C, UNC Foundations for Global Health Course
Press Mentions
- Virginia Set to Receive 20K Doses of Novavax VaccineJuly 24th, 2022
- NewsweekJanuary 5th, 2022
- Vaccines Are Coming to NC’s Prisons. Who Should Get First Priority?December 9th, 2020
- Join now to see all
Grant Support
- The Stop StudyNational Center For Hiv, Viral Hepatitis, Stds And Tb Prevention2011–2012
- Longitudinal Assessment Of Acute HIV InfectionNational Center For Research Resources2008
- Clinical Trial: Once Daily Regimen Of Didanosine, Tenofovir And EfavirenzNational Center For Research Resources2008
- Clinical Trial: ACTG A5217 - Treatment VS NO Treatment In Newly Infected HIV-1 SNational Center For Research Resources2008
- Acute HIV Infection And Early Disease Research ProgramNational Center For Research Resources2007–2008
- Once Daily Regimen Of Didanosine, Tenofovir And EfavirenzNational Center For Research Resources2007
- Intermittent VS Terminal Treatment Interruption Antiretroviral Therapy For HIVNational Center For Research Resources2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: